Margins held; Lannett integration begins, biosimilars track

Delivered ₹9,150.4 Cr, 16.3% YoY growth corroborates claim

Operating EBITDA ₹1,924 Cr (21% margin) after ₹43 Cr one-time lease loss; excl. one-time, margin ~21.4%

Delivered as stated; US organic only 8.1% (not double-digit) yet overall guidance 'double-digit' maintained, implying Lannett uplift needed

Delivered; tracking to double-digit full year

Delivered

Delivered exactly; 25.2% YoY growth outpaced revenue 16.3% due to margin expansion and mix

Closed June 29, 2026; 40% current utilization, specific synergy impact and margin blend unquantified

Delivered; from ~500M tablets FY26 to 1B+ Q1 FY27, supply now to Europe & US

June 29, 2026 post-FTC approval. Adds US platform scale, controlled substance access, respiratory portfolio, government program opportunity. SGA synergies quantified offline (~₹30-40M estimated). Near-term margin impact and utilization ramp target deferred.

4 approvals now secured (EU/UK/Canada wave-one). 2-3 US filings imminent this year. Brazil ANVISA GMP certification and LATAM oncology biosimilar commercialization underway. Regulatory pathway accelerating.

From ~500M tablets (FY26) to 1B+ Q1. Export supply to Europe and US commencing now. Target >2B tablets by EOY/mid-FY28. Strategic investment inflection to manufacturing footprint.

Q1 FY27: 8.1% YoY. Prior narrative emphasized 'double-digit' expansion. Base business resilience confirmed, but momentum slowing; Lannett integration newly material to hitting full-year targets.

Reached 20%+ (from single-digit 3-4 years ago per Subramanian). Now tracking double-digit revenue growth full year. Cost reduction and mix improvement execution validated.

FY27 expect ₹1,450-1,500 Cr (vs ₹1,600+ prior). Phase 3 clinical studies completing; transition to filing/commercialization phase. Supports margin sustainability.

All growth markets contributing in line; no single outlier. New market entry (Indonesia, China, Canada) scaling normally. Lannett Advair launching Aug 2026; rest of pipeline confidential; staggered approach.

Controlled substance quota-limited (10,000 kg US total, allocated across suppliers). Lannett ramped recently; limited upside unless quota expands or competitor defaults. PEN-G external supplies ongoing; PLI payment Sep/Mar per government policy.

40% utilization now. 12-month strategic plan in place (target % not disclosed). SGA synergies realized, procurement benefits + capacity uplift within 9 months. Margin catch-up medium-term (no specific year).

US filing imminent this year (one quarter variance). Brazil ANVISA GMP secured. EU filings on track (Denosumab, Omalizumab Q3). TheraNym Unit 1: 2028 onwards (stockpiling dependent), Unit 2: 2031 onwards. Combined $150-200M by 2032 at 35-50% EBITDA.

A1 Biochem ₹100Cr revenue (2015 founding, 800+ projects, 50+ customers); CRDMO opportunity leveraging API footprint; 5-year greenfield build now 5-year head start. Closing next 1-2 months. China: doubled to 1B+ Q1, ramping to 2B+ by EOY/mid-FY28. Canada: captive supply strategy like Europe backward integration.

Eugia: steady but single-digit growth (unit-3 remediation delays); expect ~500M+ FY27 revenue. China last year ₹7Cr EBITDA loss, this year expected positive. Lannett margin detail offered offline post-call.

Net sales $60M quarterly without other products realistic. EBITDA will be 'much higher' (specific % declined). 2200 Cr quarterly target subject to geopolitical Middle East resolution.

Phase 3 clinical studies completed (35-36% of Aurobindo R&D in biosimilars, 7 wave-one programs mostly done). FY27 expect ₹1,450-1,500 Cr (down due to phase transition). Biosimilar R&D declining; filing/implementation phase.

Lannett (350M+ capacity readily) + Aurolife unit + standby facility can meet demand. Reshoring = level playing field (all competitors same costs). Lannett acquisition leapfrogged 5-7 years vs greenfield build.

Next-wave actively in development. BP58 is Trastuzumab subcutaneous formulation (device differentiation, regulatory shift in EU allowing Phase 3 waivers). Positioning for device combos and post-2032 patent cliff. No wait-watch.

Unit 1: 2028 onwards. Unit 2: 2031 onwards. Combined 2032: $150-200M revenue at 35-50% EBITDA margins. Product mix and customer filing timelines drive specifics.

Objective and target are ₹2200 Cr quarterly. Dependent on geopolitical situation Middle East resolution.

Q1 paced at 16.3% YoY. Lannett incremental (new from Q2), Europe double-digit, growth markets 38% expected to sustain trajectory.

Current base ~$1.6B annualized (Q1 $399M × 4). Lannett adds ~$60M/Q = $1.84B+. Additional upside from respiratory portfolio and controlled substance quota expansion needed to reach $2B; timing uncertain.

Q1 11% constant currency; new launches and market share gains expected Q2+ to sustain/accelerate.

4 approvals in hand, 2-3 filings imminent this year. Regulatory pathway clear and on track per Dr. Makkapati.

Q1 achieved 21% (excl. ₹43Cr one-time). Management confident on sustained/progressive improvement from Lannett synergies, China positive pivot, Europe 20%+ all accretive.

Q1 ₹1,924Cr annualizes to ~₹7,700Cr. Target >₹8,000Cr requires stronger H2 or Lannett ramp acceleration. Achievable but tight vs guidance.

Achieved Q1. Cost reduction programs and mix improvement support continuation per Muralidharan.

Specific timeline/margin target undisclosed. SGA synergies + procurement benefits + capacity uplift expected within 9 months. Full convergence vague.

Net CapEx Q1 $78M. Unit 1 commissioned June 2026; Unit 2 construction begins Oct 2026 (if clearances secured), commissioned end 2029.

Closing next 1-2 months. Integration capex TBD to support scaling from ₹100Cr current base.

Production doubled to 1B+ Q1; capex ongoing to exceed 2B by EOY/mid-FY28.

US organic growth slowed to 8.1% YoY (vs prior double-digit narrative). Generic pricing deflation and commodity-like competition in base business. Lannett integration at 40% utilization critical to offset, but ramp timeline vague.

2-3 US biosimilar filings imminent but approval timelines and commercial ramp uncertain. Europe commercialization only 2 quarters in; tender-based sales have natural lag. No material revenue visibility before 2026-27. Regulatory risk on FTC/FDA for US filings.

Lannett current utilization 40% with specific ramp target undisclosed. EBITDA margin blend with Aurobindo portfolio unclear (Aurobindo currently higher-margin). Risk of near-term dilution if synergies don't materialize or utilization stalls.

TheraNym Units 1 & 2 represent significant capex with validation batches 2027, revenue start 2028/2031, full ramp 2032. Customer concentration risk (MSD anchor). Payback 6+ years out, subject to product filing/launch delays.

Management flagged Middle East geopolitical situation as swing factor for quarterly run-rate confidence. Europe antibiotic seasonality (Q1 weak flu season cited). Currency headwinds (Euro volatility, Indian Rupee strength).